Camrelizumab(SHR-1210)

DRUG2 trials

Sponsors

Peking University, Shanghai Jiao Tong University School of Medicine

Conditions

Acute Myeloid LeukemiaHodgkin Lymphoma

Phase 2

Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma

Peking UniversityHodgkin Lymphoma

Start: 2020-01-31End: 2022-12-31Target: 84Updated: 2020-01-23

Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia

Shanghai Jiao Tong University School of MedicineAcute Myeloid Leukemia

Start: 2020-04-25End: 2022-12-31Target: 29Updated: 2020-04-20

Related Papers

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial.

2024-03-072 citations

P1090: CAMRELIZUMAB (CAM) COMBINED WITH GEMOX CHEMOTHERAPY RESULTS IN HIGH COMPLETE METABOLIC RESPONSE RATES IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL): A PHASE II TRIAL

HemaSphere2022-06-01

CAMRELIZUMAB COMBINED WITH GEMOX IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA

Hematological Oncology2021-06-011 citations